南美洲和中美洲 T 细胞治疗市场预测至 2030 年 - 区域分析 - 按模式（研究和商业化）、治疗类型 [CAR T 细胞疗法和基于 T 细胞受体 (TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）肿瘤）
No. of Pages: 55 | Report Code: BMIRE00029318 | Category: Life Sciences
No. of Pages: 55 | Report Code: BMIRE00029318 | Category: Life Sciences
靶向治疗、更快更有效的恢复以及减少副作用是T细胞治疗的优势。在全球范围内，由于获得了各种批准，细胞疗法被广泛采用：
• 2023 年：吉利德旗下 Kite 公司宣布在沙特阿拉伯、新加坡和巴西开展业务，作为其商业扩张的一部分。 Kite 已在这三个国家提交了其 CAR T 细胞治疗产品的监管申请。
• 例如，2022年6月，百时美施贵宝的 Breyanzi (lisocabtagene maraleucel) 获得 FDA 批准，这是一种 CD19 定向嵌合抗原受体 (CAR) T 细胞疗法，用于治疗成人大 B 细胞淋巴瘤 (LBCL) 患者.
• 2022年2月，美国食品和药物管理局 (FDA) 批准 Yescarta (axicabtagene ciloleucel) CAR T 细胞疗法用于治疗一线化学免疫疗法难治或一线化学免疫疗法 12 个月内复发的大 B 细胞淋巴瘤成人患者。 Yescarta 是第一个获得国家综合癌症网络 (NCCN) 1 类推荐的 CAR T 细胞疗法。
• 2022年2月，FDA批准了ciltacabtagene autoleucel（商品名CARVYKTI）用于治疗经过四线或四线以上治疗（包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体）后复发或难治性多发性骨髓瘤的成年患者。
• 2022 年 1 月，FDA 批准 Kimmtrak (tebentafusp-tebn) 用于治疗 HLA-A*02:01 阳性的不可切除或转移性葡萄膜黑色素瘤患者。
• 2021年3月，Abecma（idecabtagene vicleucel）被FDA批准用于治疗复发或难治性多发性骨髓瘤。该疗法是一种针对 B 细胞成熟抗原 (BCMA) 的转基因自体 T 细胞免疫疗法，适用于治疗难治性多发性骨髓瘤成年患者。
因此，T 细胞疗法的批准数量不断增加正在推动市场增长。
南美洲和南美洲中美洲T细胞治疗市场仅限于巴西，因为该产品仅在该国获得批准和商业化。据《巴西癌症学杂志》报道，预计 2023 年至 2025 年将新增约 704,000 例癌症病例。据估计，巴西每年诊断出超过 12,000 例非霍奇金淋巴瘤 (NHL) 病例。巴西卫生监管机构 (ANVISA) 已在巴西批准了两种 CAR T 细胞疗法：tisagenlecleucel（诺华公司），用于治疗患有 RR B 细胞急性淋巴细胞白血病 (ALL) 的儿科患者和年轻人以及患有复发/难治性 (RR) 的成人患者弥漫性大 B 细胞淋巴瘤和 ciltacabtagene autoleucel (cilta-cel) 用于治疗复发/难治性多发性骨髓瘤 (RRMM) 患者。此外，2022年8月，吉利德旗下公司Kite通过在巴西、新加坡和沙特阿拉伯开展业务来扩大业务。 Kite 已提交其 CAR T 细胞治疗产品的监管申请。癌症和淋巴瘤病例的增加以及 T 细胞疗法的应用和临床试验数量的增加预计将在未来几年增加需求。
南美洲和南美洲中美洲 T 细胞治疗市场按治疗方式、治疗类型、适应症和国家/地区进行细分。中美洲 T 细胞治疗市场分为研究和商业化。到 2022 年，商业化细分市场将占据更大的市场份额。
根据治疗类型，South &中美洲T细胞治疗市场分为CAR T细胞治疗和T细胞受体（TCR）为主。到 2022 年，CAR T 细胞疗法领域将占据更大的市场份额。
根据迹象，South &中美洲 T 细胞治疗市场分为血液恶性肿瘤和实体瘤。到 2022 年，血液恶性肿瘤细分市场占据最大的市场份额。中美洲T细胞治疗市场仅限于巴西。巴西在南部和南部地区占据主导地位。 2022 年中美洲 T 细胞治疗市场份额。
百时美施贵宝公司、吉利德科学公司、杨森全球服务有限责任公司和诺华公司是在南美洲运营的一些领先公司。中美洲T细胞治疗市场。
Strategic insights for South & Central America T Cell Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 84.11 Million |
| Market Size by 2030 | US$ 265.59 Million |
| Global CAGR (2022 - 2030) | 15.5% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By 模式
|
| Regions and Countries Covered | 南美洲和中美洲
|
| Market leaders and key company profiles |
The regional scope of South & Central America T Cell Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
1. Bristol-Myers Squibb Co
2. Gilead Sciences Inc
3. Janssen Global Services LLC
4. Novartis AG
The South & Central America T Cell Therapy Market is valued at US$ 84.11 Million in 2022, it is projected to reach US$ 265.59 Million by 2030.
As per our report South & Central America T Cell Therapy Market, the market size is valued at US$ 84.11 Million in 2022, projecting it to reach US$ 265.59 Million by 2030. This translates to a CAGR of approximately 15.5% during the forecast period.
The South & Central America T Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America T Cell Therapy Market report:
The South & Central America T Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America T Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America T Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America T Cell Therapy Market
